Incyte (INCY)
(Delayed Data from NSDQ)
$76.13 USD
+2.01 (2.71%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $75.81 -0.32 (-0.42%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$76.13 USD
+2.01 (2.71%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $75.81 -0.32 (-0.42%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
Zacks.com featured highlights: Incyte, AMC Entertainment, Mercadolibre, PTC and Clean Harbors
by Zacks Equity Research
Zacks.com featured highlights: Incyte, AMC Entertainment, Mercadolibre, PTC and Clean Harbors
Dispose of These 5 Toxic Stocks or Sell Short for Gains
by Zacks Equity Research
Toxic stocks are susceptible to outside shocks and are loaded with huge debt.
Incyte (INCY) Reports Phase III Follow-Up Data for Jakafi
by Zacks Equity Research
Incyte (INCY) announced new 208-week (4-year) follow-up data from the phase III RESPONSE study of Jakafi.
5 Top-Ranked Drug Stocks that are Broker Favorites
by Arpita Dutt
With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.
Incyte (INCY) Initiates Essential Thrombocythemia Trial
by Zacks Equity Research
Incyte (INCY) announced that the first patient has been treated in the essential thrombocythemia trial on ruxolitinib. A potential label expansion of the drug will boost sales.
AstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS View
by Zacks Equity Research
AstraZeneca's (AZN) Q3 results were mixed. It expects 2017 core earnings to be toward the favorable end of the guidance range of a decline in low-to-mid teen percentage.
Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal
by Zacks Equity Research
Incyte Corporation (INCY) reported strong results in the third quarter on strong Jakafi sales and upped its guidance as well.
What's in the Offing for Intercept (ICPT) in Q3 Earnings?
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) is likely to see a dip in Ocaliva sales when it reports third-quarter results on Nov 1.
Zacks.com featured highlights: Incyte, Apache, Titan International, AMC Entertainment and Carbonite
by Zacks Equity Research
Zacks.com featured highlights: Incyte, Apache, Titan International, AMC Entertainment and Carbonite
What's in the Offing for Exelixis (EXEL) in Q3 Earnings?
by Zacks Equity Research
Exelixis, Inc. (EXEL) received a major boost with the FDA's approval of Cabometyx tablets and we expect investor focus on the drug's uptake when it reports third-quarter results.
Will Radius Health (RDUS) Disappoint This Earnings Season?
by Zacks Equity Research
Radius Health (RDUS) has a disappointing track record and we expect the trend to continue when it reports third-quarter results on Nov 2.
Get Rid of These 5 Toxic Stocks or Sell Short for Profit
by Zacks Equity Research
Toxic stocks are vulnerable to outside shocks and are burdened with high amounts of debts. Also, the price of toxic stocks is inflated.
Why Incyte (INCY) Might Surprise This Earnings Season
by Zacks Equity Research
Incyte (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in Store for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Alexion's (ALXN) blockbuster drug, Soliris, continues to perform well and the company is scheduled to report third-quarter 2017 results on Oct 26, before the opening bell.
Lilly (LLY) Beats on Q3 Earnings, Explores Sale of Elanco
by Zacks Equity Research
Eli Lilly (LLY) beat estimates for both sales and earnings in Q3 and upped its 2017 outlook. Separately, the company said that it is exploring strategic alternatives for the Elanco Animal Health business.
Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
5 Toxic Stocks to Abandon or Sell Short for Gains
by Zacks Equity Research
Toxic stocks are susceptible to external shocks and are loaded with high amounts of debts. Also, the price of toxic stocks is irrationally high.
Agenus (AGEN) Remains Focused on Drug Development Programs
by Zacks Equity Research
Agenus' (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.
J&J's Arthritis Candidate Sirukumab Denied FDA Approval
by Zacks Equity Research
J&J (JNJ) said that the FDA has denied approval to its investigational rheumatoid arthritis treatment, sirukumab for want of additional safety data.
Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite
by Zacks Equity Research
Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite
5 Toxic Stocks to Discard or Sell Short for Profit
by Zacks Equity Research
Toxic stocks are exposed to outside shocks and are burdened with high levels of debts. Also, the price of toxic stocks is artificially inflated.
Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study
by Zacks Equity Research
Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.
Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda
by Zacks Equity Research
Incyte Corporation (INCY) announced new and updated data from the ongoing phase I/II ECHO-202 trial on pipeline candidate epacadostat with Keytruda.
Top Research Reports for Bank of America, Pepsi & American Express
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), American Express (AXP), and Pepsi (PEP).
Lilly/Incyte to Re-File Baricitinib NDA Faster Than Expected
by Zacks Equity Research
Lilly (LLY) and Incyte announced that they will re-submit the new drug application (NDA) for their rheumatoid arthritis (RA) drug, baricitinib much faster than previously expected.